Designs, manufactures and integrates process equipment, containment systems, cleanroom partitions and utilities for pharmaceutical manufacturing facilities in emerging markets, with in-house compliance to WHO, EU-GMP, USFDA and UKMHRA standards. FY26 consolidated revenue was ₹410.77 crore, with the largest shares from Rest of the World (31.6%), UAE (27.9%) and Saudi Arabia (18.2%); India contributed 10.0%, Kenya 9.6%, with smaller contributions from Egypt (1.4%) and Algeria (1.4%). The order book stood at over ₹900 crore, giving 18-24 months of execution visibility, alongside a hot-lead pipeline of ~$200 million USD. A ₹230 crore equity infusion lifted cash and bank balances 5x to ₹208.57 crore and cut debt from ₹54 crore to ₹42 crore, leaving the balance sheet net cash. The cost structure is dominated by other operating expenses at 21.9% of revenue and employee costs at 10.5%, with raw material cost flagged as a +33% headwind and execution cost a +43% headwind during the year. The business is project-based, dependent on capex cycles of pharma customers across MENA, Africa and India. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Rest of the World (32%), UAE (28%), Saudi Arabia (18%), India (10%), Kenya (10%), Egypt (1%), Algeria (1%). Project-based, EPC-style pharma infrastructure platform with in-house manufacturing and multi-quarter execution cycles
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 411 |
| EBITDA (ex other income) | 37 |
| margin % | 9.0 |
| Owners' profit | 38 |
| EPS, as reported (₹) | 10.00 |
| ROE % · ROCE % | 9.1 · 11.6 |
| Debt / equity (x) | 0.10 |
| Cash from operations | 0 |
| Capex | (5) |
| ₹ crore | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|
| Revenue | 68 | 121 | 63 | 159 | 75 |
| Profit before tax | (6) | 31 | (7) | 30 | 5 |
| Net profit | (6) | 28 | (6) | 22 | 4 |
| EPS (₹) | (1.89) | 8.68 | (1.56) | 5.75 | 0.95 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| India | 45 | 10.0 |
| Saudi Arabia | 83 | 18.2 |
| UAE | 127 | 27.9 |
| Kenya | 43 | 9.6 |
| Algeria | 6 | 1.4 |
| Egypt | 6 | 1.4 |
| Rest of the world | 70 | 15.4 |
| Sri Lanka | 1 | 0.3 |
| Rest of the World | 72 | 15.9 |
| Total, before eliminations | 454 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 17,626 | 55.9 | 5.60 | 32.3 | 10.2 | 12.6 | 19.0 | 30.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Fabtech UAE subsidiary completes 14000 sqm Himalaya cleanroom facility | compliance | low | — | — |
| 26 Aug 2026 · Fabtech shareholders approve all five AGM proposals | compliance | minimal | — | — |
| 24 Aug 2026 · Reappointment of Directors approved at AGM | management changes | medium | — | — |
| 24 Aug 2026 · 8th AGM held; final dividend of Rs 0.60 per share declared | board shareholder meetings | low | — | — |
| 19 Aug 2026 · Fabtech UAE unit bags AED 9.92M flavour manufacturing project | business updates | high | — | — |
| 3 Aug 2026 · Fabtech Technologies Q1 FY27 earnings call transcript | investor communications | medium | — | — |
| 1 Aug 2026 · Fabtech Technologies 8th AGM on Aug 24, 2026; dividend record date Aug 17 | compliance | minimal | — | — |
| 1 Aug 2026 · AGM notice, record date Aug 17 and e-voting details published | compliance | minimal | — | — |
| 31 Jul 2026 · Fabtech Technologies AGM Notice and Annual Report FY2025-26 filed | board shareholder meetings | medium | — | — |
| 30 Jul 2026 · Fabtech Technologies publishes notice for 8th AGM in newspapers | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| FISCHER MEDICAL VENTURE L |
| 2,353 |
| 15.0 |
| 6.11 |
| 43.6 |
| 8.1 |
| 11.3 |
| — |
| 15.5 |
| TARSONS PRODUCTS LIMITED | 1,657 | 149.0 | 2.61 | 14.3 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 1,121 | 36.0 | 4.59 | 24.1 | 11.8 | 11.0 | — | 22.3 |
| FABTECH TECHNOLOGIES LTD ◆ | 650 | 10.6 | 1.55 | 10.6 | 9.1 | 10.7 | — | 9.9 |
| Hemant Surgical Industries Lim | 613 | 23.4 | — | — | — | 16.7 | — | — |
| Prevest Denpro Limited | 489 | 16.5 | — | — | — | 21.9 | — | — |
| NURECA LIMITED | 318 | 65.2 | 1.76 | 38.3 | 1.2 | 2.7 | (7.2) | 13.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 10.6 | 20.0 | 3 of 17 | 88% |
| P/B | 1.6 | 2.7 | 3 of 11 | 80% |
| ROCE | 10.7 | 11.3 | 12 of 17 | 31% |
| ROE | 9.1 | 8.1 | 5 of 11 | 60% |
| Debt / Equity | 0.1 | 0.1 | 5 of 11 | 60% |
| EBITDA margin | 9.9 | 16.7 | 10 of 11 | 10% |
| Revenue growth | 10.3 | 13.9 | 10 of 13 | 25% |
| Profit growth | 168.7 | 75.5 | 3 of 10 | 78% |
| Market cap | 650 | 175 | 5 of 17 | 75% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
